Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule

Cancer Immunology Immunotherapy

Volumn 42, Issue 3, 1996, Pages 161-169

  La Motte, Ross N ^a   Rubin, Michael A ^a   Barr, Eliav ^b   Leiden, Jeffrey M ^b   Bluestone, Jeffrey A ^b   Mokyr, Margalit B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

B7 1 and B7 2 costimulatory molecules; tumor vaccine; tumor eradicating immunity

Indexed keywords

CANCER VACCINE; CELL ADHESION MOLECULE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; INTRAPERITONEAL DRUG ADMINISTRATION; MASTOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; FEMALE; IMMUNOTHERAPY, ACTIVE; MAST-CELL SARCOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED DBA; TRANSFECTION;

EID: 0029916084     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050266     Document Type: Article

References (32)

1. Allison JP, Hurwitz AA, Leach DR (1995) Manipulation of costimulatury signals to enhance antitumor T-cell responses. Current Opin Immunol 7:682
2. Azuma M, Cayabyab M, Buck D, Philips JH, Lanier LL (1992) CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 175:353
3. Azuma M, Ho D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76
4. Barr E, Carrol J, Tripathy SK, Kozarsky K, Wilson J, Leiden JM (1994) Precutaneous transluminal gene transfer into the heart using replication-detective recombinant adenovirus. Gene Ther 1:51
5. Bluestone JA (1995) New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555
6. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM (1995) Cytostatic gene therapy for vascular proliferative disorders with a consitutively active form of retinoblastoma gene product. Science 267:518
7. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE (1994) B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Coynebacterium parvum. Cancer Res 54:5420
8. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE (1994) Tumor immunogenicity determines the effect of B7 costimulation of T cell-mediated immunity. J Exp Med 179:523
9. Corry DB, Reiner SL, Linsley PS, Locksley RM (1994) Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J Immunol 153:4142.
10. Freeman GJ, Gray GS, Gimmi CD, Lombard DB, Xhou LJ, White M, Fingeroth JD, Gribben JG, Nadler LM (1991) Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 174:625
11. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo JA, Lombard LA, Gray GS, Nadler LM (1993) Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909
12. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke X-Y, Rennert PD, Gray GS, Gribben JG, Nadler LN (1995) B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulate the initial production of IL-4. Immunity 2:523
13. Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ (1993) Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262:905
14. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ (1994) Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 180:631
15. Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia virus expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552
16. Horst H-A, Scheithauer BW, Kelly PJ, Kovach JS (1992) Distribution of transforming growth faclor-β in human astrocytomas. Hum Pathol 23:1284
17. June CH, Bluestone JA, Nadler LM, Thompson CB (1994) The B7 and CD28 receptor families. Immunol Today 15:321
18. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: Application to autoimmune disease therapy. Cell 80:707
19. Lenschow DJ, Su GH-T, Zuckerman LA, Nabavi N, Jellis CL, Gray GS, Miller J, Bluestone JA (1991) Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci USA 90:11-182
20. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA (1995) Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment in the development of diabetes in the nonobese diabetic mouse. J. Exp Med 181:1145
21. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R (1994) Human B7-1 (CD80)and B7-2(CD86) bind with similar avidity but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793
22. Powers GD, Faherty DA, Connaughton SE, Biondi DA, Godfrey DI, Gault A, Chen C-Y, Nabavi N (1994) Expression and functional analysis of murine B7 delineated by a novel monoclonal antibody. Cell Immunol 153:298
23. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW (1993) Different T cell costimulatory requirements in CD28-deficient mice. Science 261:609
24. Sulitzeanu D (1991) Immunosuppressive factors in human cancer. Adv Cancer Res 60:247
25. Thompson CB (1995) Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81:979
26. + T cells by B7-transfected melanoma cells. Science 259:368
27. Townsend SE, Su FW, Atherton JM, Allison JP (1994) Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54:647
28. Tripathy SK, Goldwasser E, Lu M-M, Barr E, Leiden J (1994) Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci USA 91:11 557
29. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T (1991) The gene encoding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173:1373.
30. Weiskirch L, Bar-Dagan Y, Mokyr MB (1994) Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol Immunother 38:215
31. Wu T-C, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM (1995) A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182:1415
32. Yang G, Hellstrom KE, Hellstrom I, Chen L (1995) Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA4 costimulatory molecules. J Immunol 154:2794